Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
The Low-EPI Study is a research project focusing on people who have a sudden cardiac arrest away from a hospital setting. When someone's heart stops suddenly, emergency teams often give a medicine called adrenaline (epinephrine) to try and restart it. This study is testing if using a lower dose of adrenaline might lead to better recovery, especially for brain function, 28 days after the cardiac arrest, compared to the standard dose. It's a large, carefully designed study involving many hospitals, and neither the patients nor the doctors will know who is receiving which dose, to ensure fair results. The main goal is to see if patients not only survive but also have a good quality of life afterwards.
At a glance
What is this study about?
When someone has a cardiac arrest, their heart suddenly stops pumping blood around their body. This is a very serious emergency, often happening outside of a hospital, like at home or in a public place. Emergency services will try to restart the heart, often using CPR (cardiopulmonary resuscitation) and sometimes giving medicines. One of the main medicines given is called adrenaline, also known as epinephrine.
This study, called the Low-EPI Study, is looking into how effective different doses of adrenaline are in helping people recover after an out-of-hospital cardiac arrest. Specifically, it wants to find out if using a lower dose of adrenaline might lead to better overall recovery, especially how well a person's brain functions after the event, compared to the standard dose. Everyone involved hopes to improve the chances of not just surviving a cardiac arrest, but also having a good quality of life afterwards.
To make sure the results are as clear and reliable as possible, this study is 'randomized' and 'double-blind'. This means that people in the study will be randomly assigned to receive either the lower dose or the standard dose of adrenaline, by chance. Also, neither the emergency medical staff providing the treatment nor the patients (if they recover sufficiently to understand) will know which dose is being given. This helps prevent any bias and ensures we can truly understand the effects of the different doses.
Key takeaways
- This study explores if a lower dose of adrenaline (epinephrine) improves recovery from cardiac arrest.
- It focuses on out-of-hospital cardiac arrests and brain function after 28 days.
- The study is 'double-blind', meaning no one knows which dose is given at the time.
- It aims to improve survival and quality of life for cardiac arrest patients.
- The main goal is to see if patients survive with good brain function.
- Participation would happen during the emergency, with follow-up for 28 days.
Who may be eligible?
This study is designed for adults who experience a sudden cardiac arrest outside of a hospital. To be included, you would need to be at least 18 years old.
The study includes both men and women. The specific decision to include you would be made by the medical team at the time of your cardiac arrest, based on whether you meet the study's scientific criteria.
Since this is an emergency situation, consent for participation might be obtained from family members or legal guardians, or deferred until after initial treatment, as dictated by ethical guidelines for emergency research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Did the cardiac arrest happen outside of a hospital?
- Is it a sudden cardiac arrest?
- Are you male or female?
What does participation involve?
If you or someone you care for were to participate in this study, it would happen at the time of an out-of-hospital cardiac arrest. Emergency medical staff would administer either the standard dose or a lower dose of adrenaline as part of the emergency treatment. Besides this, there wouldn't be any extra visits or appointments specifically for the study at that immediate time.
After the cardiac arrest, if you survive and are admitted to hospital, doctors would monitor your progress closely. One of the main things they'd be looking at is your recovery and how well your brain is functioning, particularly 28 days after the event. This would involve standard medical assessments that you would likely receive anyway as part of your ongoing care after such a serious event. The total duration of the key follow-up for the study would be up to 28 days.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is 'out-of-hospital cardiac arrest'?
It's when your heart suddenly stops beating effectively while you are outside of a hospital, often in your home or a public place.
What is adrenaline (epinephrine) and why is it used?
Adrenaline is a hormone and medicine often given by emergency teams to try and restart the heart and improve blood flow during a cardiac arrest.
What does 'favourable neurological function' mean?
This refers to how well your brain works after the event. A 'favourable' outcome means you can largely look after yourself and participate in daily activities, without severe disability.
What is a 'Modified Rankin Scale (mRS) score'?
It's a common scale doctors use to measure how much disability a person has after a stroke or similar brain injury, ranging from no symptoms to severe disability.
Will I know if I'm getting the lower dose or standard dose?
No, this study is 'double-blind', meaning neither you nor the medical staff will know which dose is being given until after the study is over, to ensure unbiased results.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.